Hair Loss Is Not One Thing

Hair loss is often spoken about as if it were a single problem. It is not.

For some women, it begins suddenly: hair on the pillow, hair in the shower drain, hair gathered around the fingers after washing. For others, it is quieter. The part slowly widens. The ponytail feels thinner. The scalp becomes more visible under bright bathroom light.

Both experiences can be called hair loss, but they are not always the same biological event.

This article focuses on two common patterns in women: telogen effluvium, which is usually sudden shedding after a trigger, and female pattern hair loss, also called female androgenetic alopecia, which is usually gradual thinning caused by follicle miniaturisation. ^{[4, 5]}

They can occur separately. They can also overlap. A period of stress, illness or postpartum shedding may reveal an underlying pattern of thinning that was already beginning quietly.

Before speaking about treatments, it helps to understand what is happening beneath the surface - inside the tiny structure where hair growth begins: the follicle.

What happens beneath the surface

A follicle is a little like a pen cap gripping a pen. It anchors the hair root in place, receives signals from the body, and helps decide when that hair grows, rests and sheds.

This is why hair loss is rarely only a surface problem. When people say “my hair is falling,” the problem may be happening at different levels. The follicle may be shedding a hair as part of its normal cycle. The follicle may be producing a thinner hair than it used to. Or the strand may be breaking from friction, heat, humidity, chemical damage or tight styling.

These all feel similar in daily life, but biologically they are different.

This distinction is especially relevant in Singapore. Humidity can swell the hair fibre, increase frizz, worsen tangling and make breakage more visible. But breakage is not the same as follicular hair loss. One happens along the strand. The other begins in the scalp.

Anagen, telogen and exogen

Hair does not grow continuously forever. Each follicle moves through a cycle.

The most important phase is anagen, the active growth phase. An easy way to remember it is: A = active, Gen = generation. This is when the follicle is actively generating the hair fibre. Scalp hair can remain in anagen for years, often described as two to seven years. The length of anagen helps determine the potential length of the hair.

Then comes telogen, the resting phase. Telogen usually lasts a few months. Around 10-15% of scalp hairs may be in this phase at a time. The follicle is not actively growing a new fibre during telogen. Eventually, the resting hair is shed. ^[4]

There is also exogen, the shedding phase. For simplicity, most people speak about anagen and telogen, but exogen is the moment we actually notice: the hair in the comb, the hair on the floor, the hair in the shower.

The goal of treatment is therefore not always simply to stop hair fall. Hair is meant to shed. The question is whether the cycle has become imbalanced, whether the follicle has miniaturised, or whether the body is reacting to a trigger.

Telogen effluvium: when more follicles rest

Telogen effluvium is diffuse shedding. It often appears two to three months after a trigger: childbirth, severe stress, fever, infection, surgery, crash dieting, iron deficiency, thyroid imbalance, medication changes or another physiological shock.

The follicle is not usually destroyed. Instead, a larger-than-usual number of follicles shift from anagen (generation) into telogen (rest). Months later, those resting hairs shed together.

This is why telogen effluvium can feel delayed and mysterious. The shedding may begin when life is already back to normal, even though the trigger happened earlier.

Postpartum shedding is a classic example. During pregnancy, hormonal changes can keep more hairs in the growth phase. After childbirth, hormonal shifts can cause many hairs to enter shedding more synchronously. The experience can be emotionally intense, especially when it happens around the hairline, but it is often temporary. ^[2]

The most important treatment is identifying and correcting the trigger. If the trigger has passed and the follicle is healthy, regrowth often begins gradually. But the hair cycle takes time, so recovery is measured in months, not days. ^[4]

Female pattern hair loss: when follicles miniaturise

Female pattern hair loss is different. It usually appears as progressive thinning over the central scalp, widening of the part, reduced ponytail volume or more visible scalp under light. The frontal hairline is often relatively preserved, though this is not always the case.

The key event is miniaturisation. Miniaturisation does not mean the hair immediately sheds. It means the follicle keeps cycling, but each cycle produces a thinner, shorter hair. Shedding may still happen later as part of the normal cycle, but the more important change is gradual: the follicle is no longer making the same kind of strong terminal hair it once did.

Androgens - hormones associated with male-typical traits but naturally present in both men and women — may play a role in this process. In female pattern hair loss, the issue is often not simply too much androgen in the blood. It may be that certain follicles are more sensitive to normal androgen signals, which can gradually shorten the growth phase and produce thinner, finer strands. ^[5]

Because female pattern hair loss can look like ordinary shedding in the beginning, the next question is not which product should I buy, but what kind of hair loss is this?

A home signal: the pull test

A healthy person has about 100,000 hair strands and may lose around 50-100 hairs a day while growing new ones. Long hair can make this look more dramatic, especially after washing or brushing. A simple pull test can offer a signal, not a diagnosis.

With dry hair, grasp a small bundle close to the scalp and gently but firmly pull along the length of the shaft. Repeat this across ten different parts of the scalp. If more than 5 hair strands come away per pull, especially across multiple areas, it may suggest active shedding and is worth discussing with a dermatologist. ^[3]

The pull test is not meant to replace diagnosis. It simply helps separate ordinary daily shedding from a pattern that deserves a closer look.

When shedding needs a closer look

It is tempting to begin with products. Diagnosis is usually the better first step.

A dermatologist may examine the scalp with trichoscopy, a magnified view that can show miniaturisation, variation in hair-shaft diameter, inflammation, scaling, scarring or signs of another condition. A pull test, wash test or clinical history may help distinguish shedding from patterned thinning.

Blood tests may be useful when telogen effluvium is suspected, especially if the shedding is sudden, diffuse or prolonged. Common checks include complete blood count, ferritin or iron studies, thyroid function and, where relevant, vitamin D, B12 or hormonal evaluation. Hormonal testing may be especially relevant if hair loss appears with irregular periods, acne, increased facial hair or signs of PCOS.

See a dermatologist promptly if there are bald patches, scalp pain, burning, heavy scaling, pus, broken hairs, eyebrow loss, rapid progression, or shiny areas where follicles seem to have disappeared. These may point to conditions outside the scope of cosmetic care. ^{[4, 5]}

What treatments can actually do

Most treatments for female pattern hair loss are maintenance treatments, not cures. They help the follicle behave better while they are used. If they are stopped, the benefit may gradually be lost. ^[5]

Telogen effluvium is different. If the trigger is found and corrected - childbirth, illness, nutritional deficiency, thyroid imbalance, crash dieting, medication change or severe stress - the shedding may settle because the disruption has passed. ^[4]

This is why the same ingredient can be useful for different reasons. One treatment may help move follicles back toward anagen. Another may protect against miniaturisation. Another may improve scalp comfort or reduce breakage, making the hair that remains look and feel fuller.

The following list is not exhaustive. It focuses on the treatments and molecules most relevant to women thinking about stress-related shedding, postpartum shedding, humidity-related breakage and gradual thinning.

Medical treatments

Topical minoxidil

Topical minoxidil is the most established medical treatment for female pattern hair loss. It appears to help by prolonging anagen, supporting miniaturised follicles and increasing the proportion of hairs in active growth. Its strongest evidence is for pattern loss, not merely temporary shedding. Because systematic reviews and randomised trials support its use, it sits in the strongest evidence category, Level 1, when those trials are reviewed together. ^[6]

Minoxidil has an unusual history. It began as an oral blood-pressure medicine, and hair growth was first noticed as a side effect. That history also explains why the oral version needs more caution.

Topical minoxidil can be effective, especially when started early, but it usually has to be continued. If it is stopped, the benefit may gradually be lost and the underlying pattern of thinning may resume.

Topical minoxidil may cause scalp itching, flaking, dryness or irritation, and some users experience temporary increased shedding in the first weeks as follicles shift cycle. Unwanted facial hair can occur if the product spreads beyond the scalp. Rarely, people may develop allergic contact dermatitis, often related to the formula or solvent rather than minoxidil alone. ^[7]

Low-dose oral minoxidil

Low-dose oral minoxidil works through the same broad growth-supporting pathway, but because it acts systemically, it belongs firmly in doctor-guided territory. It may be considered when topical minoxidil is irritating, cosmetically difficult to use, or not practical for long-term adherence.

Its evidence is stronger than simple observational evidence, but still less mature than topical minoxidil for women. Low-dose oral minoxidil has been tested in small randomized human trials in women with female pattern hair loss, including dose-comparison and oral-versus-topical studies. For this article, it is best described as Strong but early, Level 2: it has human comparison-trial evidence, but the studies are still small, relatively short and doctor-guided. It is most relevant to pattern loss, not as a quick fix for temporary postpartum shedding.

Oral minoxidil can cause unwanted facial or body hair growth, which is one of the most reported effects. Some users may also experience ankle swelling, fluid retention, dizziness, headache, palpitations or a faster heartbeat. Because it acts systemically and was originally a blood-pressure medicine, it should be used only under medical supervision, especially in people with heart, blood-pressure, kidney or fluid-retention concerns. ^[8]

Finasteride

Finasteride works on miniaturisation, not telogen shedding. It lowers DHT, the androgen signal strongly associated with follicle miniaturisation in male pattern hair loss. In that context, the evidence is strong.

For women, the picture is much less straightforward. A randomized study of 1 mg finasteride in postmenopausal women did not show benefit, while higher-dose use in selected women is based on weaker, specialist-guided evidence. So the simplest honest statement is this: finasteride is established for men, but limited and mixed for women. It should not be presented as a standard women-first solution.

Finasteride is not appropriate during pregnancy because of the risk of birth defects in a male fetus. In women of childbearing potential, it should only be considered with specialist guidance and reliable contraception. Other reported side effects include reduced libido, breast tenderness, headache, gastrointestinal discomfort, dizziness, mood changes and menstrual changes, though female-specific safety data is much thinner than male data. ^[9]

Microneedling with minoxidil

Microneedling creates controlled micro-injuries in the scalp. The purpose is not simply to irritate the skin. The theory is that controlled injury can trigger wound-healing signals and improve the penetration or effect of topical minoxidil.

The evidence is strongest when microneedling is paired with minoxidil, not when it is used alone. It is therefore best framed as a pattern-loss adjunct. Systematic reviews of randomized trials place the combination in the strongest category, Level 1, but real-world results depend heavily on technique, hygiene, depth, frequency and whether the scalp is inflamed. Incorrect technique can cause infection, scarring or worsening irritation.

Microneedling commonly causes temporary redness, tenderness, pinpoint bleeding or scalp discomfort after treatment. When combined with minoxidil, itching or irritation can also occur, and this may come from the minoxidil, the needling, or both. The more serious risks are infection, prolonged inflammation or scarring, especially when performed too aggressively, on an inflamed scalp, or with poor hygiene. ^[10]

Cosmetic clinical actives

Redensyl

Redensyl is a branded cosmetic complex usually described as acting on follicle stem-cell and dermal papilla pathways. Its appeal is clear: it speaks the language of follicle biology rather than surface gloss alone.

But the evidence remains early. Some small trials and formulation studies report improvement in hair parameters, and recent reviews include Redensyl among topical alternatives. Still, much of the evidence is small, formulation-specific or tested in combinations where it is difficult to know which ingredient caused the result. Redensyl is best framed as early clinical, Level 4: an interesting thinning-support active, not a proven substitute for minoxidil.

The available clinical studies of Redensyl-containing formulas report good tolerability, with no product-related adverse effects reported. ^{[11, 12]}

Anagain

Anagain is a pea sprout extract that may help the follicle’s internal growth signals that encourage hair to stay in the active growth phase, shifting the anagen-telogen balance.

A small human study using oral pea sprout extract reported reduced hair loss after eight weeks, with no adverse events reported. Because this was a small pilot study without a strong comparison group, it is best described as Early clinical, Level 4: human evidence exists, but it is not yet strong controlled proof.

In the small clinical study on oral pea sprout extract, no adverse events were reported, but that does not prove long-term safety across all doses, formats or populations. ^[13]

Caffeine

Caffeine is often misunderstood because it appears in shampoos and serums that make very broad claims. The more serious scientific argument is that caffeine appears to work more broadly as a follicle stimulant, influencing cellular activity and growth-related signalling, especially in androgenetic alopecia.

A caffeine-based topical liquid was studied in men with androgenetic alopecia and considered non-inferior to 5% minoxidil in that trial. That gives caffeine human clinical relevance, but the result should be read carefully: the study was male-focused and formula-specific. For women, caffeine is best framed as pattern-loss support with strong but indirect Level 2 evidence, not as a proven female-pattern hair-loss treatment.

Topical caffeine preparations appear to be generally well tolerated in the available hair-loss studies, with minimal adverse effects reported. ^[14]

Botanical actives

Amla

Amla, or Phyllanthus emblica, is traditionally valued in India and is rich in polyphenols with antioxidant activity. For hair, the proposed logic is not simply nutrition. Oxidative stress, inflammation and follicle signalling may all influence the hair cycle, so an antioxidant-rich botanical could plausibly support the follicle environment.

What makes amla especially interesting is that it has moved beyond only traditional or animal evidence. A randomized, triple-blind, placebo-controlled human trial studied an oral amla preparation in women with female androgenetic alopecia and reported improvement in the anagen phase. This places that specific amla preparation in strong but early Level 2 evidence: tested in a randomized human trial, but still small (60 women) and in need of replication. It is therefore one of the more serious botanicals in this article - comparable to some synthetic options in evidence level, but not yet in evidence weight.

The oral amla study in women with female androgenetic alopecia reported good tolerability and no side effects, but the evidence is still specific to that preparation and dose. ^[15]

Rosemary oil

Rosemary oil is best framed as pattern-loss support, not telogen-effluvium treatment. Its most cited study compared rosemary oil with 2% minoxidil in androgenetic alopecia over six months. That gives it a real clinical signal, but the evidence base is thin and often over-amplified on social media.

The honest position is not that rosemary oil is useless, nor that it is a minoxidil replacement. It is a botanical with strong but thin Level 2 evidence from a small comparative trial. The biggest practical caution is formulation. Essential oils can irritate or sensitise the scalp, especially when used undiluted or in aggressive DIY mixtures. ^{[16, 22]}

Centella asiatica

Laboratory studies suggest Centella asiatica may influence the cells at the base of the follicle that help control hair growth. This makes it biologically interesting for pattern thinning, but the evidence for Centella alone is not yet strong enough to treat it as a proven hair-loss active. ^[17]

A recent exploratory randomized human trial makes the case stronger than lab evidence alone, but the study did not use a standard plant extract. It used Centella-derived extracellular vesicles, or EVs — tiny messenger particles that may improve stability, absorption and delivery. This matters because it limits the claim: the evidence applies to a specialised Centella-derived particle formula, not to ordinary Centella extracts in general. ^[18]

The evidence is best described as Strong but early, Level 2 for the specific Centella-derived EV formula tested in that trial, and Mechanistic or preclinical, Level 5 for ordinary Centella extracts used as hair-loss actives.

When applied topically, Centella asiatica is generally well tolerated, but rare cases of burning sensation, skin allergy and allergic contact dermatitis have been reported. ^[19]

Ashwagandha

Topical ashwagandha serum has a small, randomized placebo-controlled study showing improvement in hair-growth and hair-health indicators. That makes topical ashwagandha Strong but early, Level 2, for the tested serum.

Its proposed mechanism is partly stress-linked and partly follicle-linked. Ashwagandha may help the body regulate stress responses which makes it relevant to stress-related shedding, where cortisol and physiological stress can push more follicles into the resting phase. Topically, the tested serum may also support the scalp and follicle environment through antioxidant and anti-inflammatory effects associated with withanolides, the best-known active compounds in ashwagandha. This makes it best framed as stress-related shedding support and possible follicle-environment support, not as a proven anti-miniaturisation treatment.

Topical ashwagandha products may cause irritation or allergy depending on the overall formula. ^[20]

Comparison table

Approximate monthly cost is normalised to one month of use. If a product lasts two months, the monthly cost is counted as half the retail price. For cosmetic products, the estimate assumes a premium-positioned product rather than the cheapest marketplace option. Prices are directional and can change by clinic, prescription status, channel and dosage. ^[21]

The quiet truth: hair takes time

Hair loss treatments are slow because follicles are slow. A follicle cannot be hurried into producing a long, thick strand overnight. Even when a treatment works, the first visible signs may be reduced shedding, tiny regrowth, improved density under trichoscopy or a slightly fuller part line months later.

This is why before-and-after claims can be misleading. A good treatment plan usually asks for patience, consistency and correct diagnosis. It also asks for emotional steadiness, which is difficult when hair loss is visible every day.

For many women, the first step is not finding the strongest ingredient. It is identifying the right kind of hair loss.

If the issue is telogen effluvium, the body may need recovery, nutrition, time and removal of the trigger. If the issue is female pattern hair loss, the follicle may need long-term support before miniaturisation progresses. If both are present, postpartum or stress-related shedding may reveal an underlying patterned thinning that was already beginning quietly. ^{[4, 5]}

Hair loss is not one thing. That is why the answer should not be one thing either.

Editorial note

This article is educational and should not be read as diagnosis or medical advice. Hair loss can be caused by deficiencies, thyroid disease, PCOS, medication changes, inflammatory scalp disease, autoimmune conditions, pregnancy-related changes and other medical issues. Persistent, rapid, painful, patchy or scarring hair loss should be assessed by a dermatologist.

The article intentionally avoids product recommendations. Its role is to help the reader understand the condition, the evidence and the realistic limits of each category of care.

Source notes

1. Oxford Centre for Evidence-Based Medicine, OCEBM Levels of Evidence. https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebm-levels-of-evidence
2. American Academy of Dermatology Association, normal hair shedding and telogen effluvium overview. https://www.aad.org/public/diseases/hair-loss/insider/shedding
3. Singh S et al., Practical Approach to Hair Loss Diagnosis, including pull-test interpretation. https://pmc.ncbi.nlm.nih.gov/articles/PMC8719967/
4. Hughes EC et al., Telogen Effluvium, StatPearls/NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK430848/
5. Ramos PM et al., Female-pattern hair loss: therapeutic update, 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10334345/
6. Adil A, Godwin M., systematic review and meta-analysis of treatments for androgenetic alopecia, including topical minoxidil. https://pubmed.ncbi.nlm.nih.gov/28396101/
7. Patel P et al., Minoxidil, StatPearls/NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK482378/
8. Gupta AK et al., low-dose oral minoxidil review and adverse-effect profile. https://pmc.ncbi.nlm.nih.gov/articles/PMC10806356/
9. Iorizzo M et al., Finasteride treatment of female pattern hair loss; female evidence and specialist-use context. https://jamanetwork.com/journals/jamadermatology/fullarticle/403800
10. Ahmed KMA et al., combined microneedling therapy versus topical minoxidil systematic review and meta-analysis. https://pmc.ncbi.nlm.nih.gov/articles/PMC11890238/
11. Bikash C et al., Topical Alternatives for Hair Loss: Beyond the Conventional. https://pmc.ncbi.nlm.nih.gov/articles/PMC12251978/
12. Katoulis AC et al., randomized, single-blinded, vehicle-controlled study of a topical active blend in androgenetic alopecia; and Merja et al., Redensyl/AnaGain/Procapil/Capilia longa serum tolerability. https://pubmed.ncbi.nlm.nih.gov/32473084/ ; https://pubmed.ncbi.nlm.nih.gov/38050644/
13. Grothe T et al., pea sprout extract clinical evaluation in hair loss. https://pubmed.ncbi.nlm.nih.gov/31680356/
14. Dhurat R et al., caffeine-based topical liquid versus 5% minoxidil in male androgenetic alopecia. https://pmc.ncbi.nlm.nih.gov/articles/PMC5804833/
15. Akhbari M et al., oral amla product in female androgenetic alopecia randomized controlled trial. https://pubmed.ncbi.nlm.nih.gov/37487962/
16. Panahi Y et al., rosemary oil versus 2% minoxidil in androgenetic alopecia. https://pubmed.ncbi.nlm.nih.gov/25842469/
17. Choi YM et al., Centella asiatica extract and human dermal papilla cells. https://www.tandfonline.com/doi/full/10.1080/09168451.2017.1385383
18. Chang TM et al., Centella asiatica extracellular-vesicle and growth-factor essence exploratory randomized trial. https://www.mdpi.com/2079-9284/12/6/253
19. Centella asiatica safety context: pharmacological review and allergic contact dermatitis report. https://pmc.ncbi.nlm.nih.gov/articles/PMC3116297/ ; https://pubmed.ncbi.nlm.nih.gov/8766746/
20. Yerram C et al., topical Withania somnifera root extract serum and hair growth indicators. https://pubmed.ncbi.nlm.nih.gov/38006746/
21. Singapore public price examples used directionally for cost normalization: Watsons Regaine 5% 60 ml, SL Aesthetic oral hair-loss medication pricing, Apax finasteride pricing, and TrichoLab / SL Clinic microneedling pricing. https://www.watsons.com.sg/regaine-extra-strength-minoxidil-topical-solution-5-w-v-solution-for-hair-regrow-hair-loss-treatment-60ml/p/BP_10858 ; https://slclinic.com.sg/hair/hair-loss-medication/ ; https://apaxmedical.com/finasteride-hair-loss-treatment/ ; https://www.tricholab.com.sg/signature-microneedling-hair-growth/ ; https://slclinic.com.sg/rf-gold-microneedling-for-hair-loss/
22. Sindle A et al., Art of Prevention: Essential Oils — Natural Products Not Necessarily Safe, contact-allergy context. https://pmc.ncbi.nlm.nih.gov/articles/PMC8243157/